Elevated Triglycerides (Hypertriglyceridemia) Clinical Trials

A listing of Elevated Triglycerides (Hypertriglyceridemia) medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.

 

Colorado

Research Center
Aurora Colorado

A Randomized, Double-Blind, Placebo-Controlled, with an Open Label Extension, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients With Familial Partial Lipodystrophy

Florida

Metabolic Research Institute, Inc.
West Palm Beach Florida 33401

Previous heart attack or stroke? Cardiovascular disease? Diabetes? Elevated blood sugar levels?

Georgia

NeuroStudies.net, LLC
Decatur Georgia 30033

Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of A Study Compound, In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects

Indiana

Community Clinical Research Center
Muncie Indiana 47304

Outcomes Study to Assess Statin Residual Risk Reduction With Epanova in High CV Risk Patients With Hypertriglyceridemia (STRENGTH)

Michigan

Research Center
Ann Arbor Michigan

A Randomized, Double-Blind, Placebo-Controlled, with an Open Label Extension, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients With Familial Partial Lipodystrophy

Northern Pines Health Center, PC
Buckley Michigan 49620

Pemafibrate (K-877) to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes.

Minnesota

Research Center
Rochester Minnesota

A Randomized, Double-Blind, Placebo-Controlled, with an Open Label Extension, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients With Familial Partial Lipodystrophy

Missouri

Research Center
St. Louis Missouri

A Randomized, Double-Blind, Placebo-Controlled, with an Open Label Extension, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients With Familial Partial Lipodystrophy

New York

Research Center
Albany New York

A Randomized, Double-Blind, Placebo-Controlled, with an Open Label Extension, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients With Familial Partial Lipodystrophy

Texas

Research Center
Dallas Texas

A Randomized, Double-Blind, Placebo-Controlled, with an Open Label Extension, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients With Familial Partial Lipodystrophy

Global Medical Research
DeSoto Texas 75115

Cardiovascular Events, Diabetes and High Triglycerides

Utah

Advanced Clinical Research
West Jordan Utah 84088

Hypertriglyceridemia Research Study

Belgium

Research Center
Leuven International

A Randomized, Double-Blind, Placebo-Controlled, with an Open Label Extension, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients With Familial Partial Lipodystrophy

Canada

Research Center
Chicoutimi, Quebec International

A Randomized, Double-Blind, Placebo-Controlled, with an Open Label Extension, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients With Familial Partial Lipodystrophy

Research Center
Halifax, Nova Scotia International

A Randomized, Double-Blind, Placebo-Controlled, with an Open Label Extension, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients With Familial Partial Lipodystrophy

Research Center
London, Ontario International

A Randomized, Double-Blind, Placebo-Controlled, with an Open Label Extension, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients With Familial Partial Lipodystrophy

Italy

Research Center
Bologna International

A Randomized, Double-Blind, Placebo-Controlled, with an Open Label Extension, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients With Familial Partial Lipodystrophy

Research Center
Catania International

A Randomized, Double-Blind, Placebo-Controlled, with an Open Label Extension, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients With Familial Partial Lipodystrophy

Research Center
Pisa International

A Randomized, Double-Blind, Placebo-Controlled, with an Open Label Extension, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients With Familial Partial Lipodystrophy

Netherlands

Research Center
Amsterdam-Zuidoost International

A Randomized, Double-Blind, Placebo-Controlled, with an Open Label Extension, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients With Familial Partial Lipodystrophy

Portugal

Research Center
Porto International

A Randomized, Double-Blind, Placebo-Controlled, with an Open Label Extension, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients With Familial Partial Lipodystrophy

Russia

Research Center
Moscow International

A Randomized, Double-Blind, Placebo-Controlled, with an Open Label Extension, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients With Familial Partial Lipodystrophy

Spain

Research Center
Santiago de Compostela International

A Randomized, Double-Blind, Placebo-Controlled, with an Open Label Extension, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients With Familial Partial Lipodystrophy

Research Center
Sevilla International

A Randomized, Double-Blind, Placebo-Controlled, with an Open Label Extension, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients With Familial Partial Lipodystrophy